This study demonstrates that RvD2 significantly reduces pro-inflammatory cytokines such as IL-1β, IL-6, and IL-21 in ex vivo intestinal biopsies from CD patients, including those refractories to anti-TNFα therapy. Here, IL6 is linked to Cowden disease.